CTOs on the Move

Acucela

www.acucela.com

 
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.acucela.com
  • 1301 2nd Ave # 1900
    Seattle, WA USA 98101
  • Phone: 206.805.8300

Executives

Name Title Contact Details

Similar Companies

SNDL

Sundial believes in health, happiness and personal well-being. Our cannabis is carefully cultivated for modern consumers—people looking for a natural alternative that fits todays active lifestyles. We are a licensed cannabis producer based in Alberta. We combine tried-and-true heartland farming with innovative horticultural techniques to grow a select range of cannabis strains. Our focus is on consistency—a pure cannabis experience that our customers can trust and count on.

Accessity

Accessity Corp. is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Siegfried USA

Siegfried USA is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pennsville, NJ. To find more information about Siegfried USA, please visit www.siegfried-usa.com

Sarepta

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company`s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases.